Pegasus Digital Mobility Acquisition Corp. Announces Redemption Results and Confirms Voluntary Payment Amount
27.7.2023 16:37:00 EEST | Business Wire | Press release
Pegasus Digital Mobility Acquisition Corp. (NYSE: PGSS.U) (the "Company"), a special purpose acquisition company founded by Pegasus Digital Mobility Sponsor (the "Sponsor") and formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganisation or similar business combination with one or more businesses or assets (a "Business Combination"), today announced that holders of 2,195,855 of the Company's Class A ordinary shares exercised their right to redeem their shares for a pro rata portion of the funds in the Company's trust account in connection with the announcement of the further extension of the period of time the Company has to consummate its proposed Business Combination with Gebr. SCHMID GmbH (the "SCHMID Group") to December 31, 2023. As a result, approximately $53.7 million will be remaining in the Company's trust account. Following the redemption, the Company's remaining number of issued and outstanding Class A ordinary shares was 5,003,218.
Commencing on August 1, 2023 and paid on the first day of each month thereafter until the earliest of (i) the date on which the Company consummates a Business Combination or (ii) December 31, 2023, the Sponsor will deposit $150,096.54 per month into the Company's trust account, representing $0.03 (three U.S. cents) per Class A ordinary share then in issue. The contribution amount shall be made available and paid on a monthly basis after the issuance of a non-convertible unsecured promissory note from the Company to the Sponsor in connection therewith. Should the Company's Board determine that it will not be able to consummate the initial Business Combination by December 31, 2023 and that the Company shall instead liquidate, the Sponsor's obligation to continue to make such contributions shall immediately cease. If the Board determines that more time is needed to consummate the initial Business Combination, a shareholders' vote in an extraordinary general meeting will be required to change the second amended and restated memorandum and articles of association of the Company.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains statements that constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release are forward-looking statements. Forward-looking statements involve predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to certain risks and uncertainties, including but not limited to:
- the occurrence of any event, change or other circumstances that could give rise to the termination of the proposed Business Combination with the SCHMID Group;
- the outcome of any legal proceedings that may be instituted against the Company, the SCHMID Group, the combined company or others following the announcement of the Business Combination and any definitive agreements with respect thereto;
- the inability to complete the Business Combination with the SCHMID Group due to the failure to obtain approval of the shareholders of the Company or to satisfy other conditions to closing;
- changes to the proposed structure of the Business Combination with the SCHMID Group that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the Business Combination;
- the ability to meet stock exchange listing standards following the consummation of the Business Combination with the SCHMID Group;
- the risk that the Business Combination disrupts current plans and operations of the Company or the SCHMID Group as a result of the announcement and consummation of the Business Combination with the SCHMID Group;
- the ability to recognise the anticipated benefits of the Business Combination with the SCHMID Group, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees;
- costs related to the Business Combination with the SCHMID Group;
- changes in applicable laws or regulations and delays in obtaining, adverse conditions contained in, or the inability to obtain regulatory approvals required to complete the Business Combination with the SCHMID Group;
- the possibility that the Company, the SCHMID Group or the combined company may be adversely affected by other economic, business, and/or competitive factors;
- the estimates of expenses and profitability and underlying assumptions with respect to shareholder redemptions and purchase price and other adjustments; and
- other risks and uncertainties set forth in the section entitled "Risk Factors" in the Company's prospectus on Form S-1 approved by the SEC.
The foregoing list of factors is not exhaustive. The forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and the SCHMID Group and the Company assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Copies of the Company's registration statement are available on the SEC’s website, www.sec.gov.
Additional Information and Where to Find It
INVESTORS AND SECURITY HOLDERS OF THE COMPANY ARE URGED TO READ ANY DOCUMENTS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) THE COMPANY FILES WITH THE SEC CAREFULLY IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain free copies of any documents (including any amendments or supplements thereto) filed with the SEC through the website maintained by the SEC at www.sec.gov or by directing a request to investor-relations@pegasusdm.com .
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230727718177/en/
Contact information
Pegasus Contact Information
Investor Relations
investor-relations@pegasusdm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SINOVAC Regained Compliance With the Nasdaq Global Market’s Listing Requirements15.6.2026 13:00:00 EEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated June 10, 2026 (the "Notification Letter"), from Hearing Advisor of The Nasdaq Stock Market LLC., indicating that the Company has regained compliance with Listing Rule 5250(c)(1) and that the Company is therefore in compliance with the Nasdaq Global Market's listing requirements. As noted in the Hearing Panel's May 20, 2026 compliance determination, the Company remains under a Mandatory Panel Monitor pursuant to Listing Rule 5815(d)(4)(B) until May 20, 2027. The Company filed its annual report on Form 20-F for the year ended December 31, 2025 on June 5, 2026. The Notification Letter also stated that the hearing before the Hearings Panel, applied for by the Company, had accordingly been canceled. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission
KRM22 partners with Sigma AI to enhance market surveillance and risk intelligence capabilities15.6.2026 13:00:00 EEST | Press release
KRM22, the technology and software investment company focused on risk management solutions for capital markets, today announced a strategic partnership with Sigma AI, a leading provider of AI-driven financial insights, to integrate advanced news sentiment analytics into its risk management application suite. The integration marks a significant enhancement to KRM22’s capabilities, enabling clients to incorporate real-time market sentiment insights derived from global news sources directly into their risk frameworks. By leveraging Sigma AI’s proprietary natural language processing and machine learning models, KRM22 will help firms better identify emerging risks, anticipate market-moving events, and make more informed trading and compliance decisions. Advancing risk management through AI-driven sentiment analysis As part of the first phase of the collaboration, KRM22 will embed Sigma AI’s news sentiment engine within its application suite. This will provide users with actionable intellige
HUI (HUI:VSE) Merges Traditional and Crypto Finance: Commences Continuous Trading in Vienna With Leading Market Maker and Announces Impending Token Listing on Major Global Exchange15.6.2026 12:15:00 EEST | Press release
HUI S.p.A., the pioneering vertical SuperApp and SaaS company dedicated to the global Venture Capital and startup ecosystem listed on the Vienna Stock Exchange, today released its global product strategy, marking an unprecedented convergence between traditional regulated markets and decentralized finance. Driven by a +15% stock surge and the consolidation of its $25 million round a equity commitment fully subscribed by global institutional fund Nimbus Capital, the company announced its upcoming transition to continuous trading on the Vienna market in partnership with a leading European market maker, alongside the activation of the initial PUT options tied to the round. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612936893/en/ HUI (HUI:VSE) merges traditional and crypto finance: commences continuous trading in Vienna with leading market maker and announces impending token listing on major global exchange Emmanuelle Deba
Syngenta Signs MoU to Be Strategic Partner in India’s First Open-Data Agricultural Ecosystem Annam.AI15.6.2026 10:35:00 EEST | Press release
India’s agriculture sector is a global powerhouse, uniquely characterized by its massive scale, vast arable land, diverse agro-climatic zones and rich biodiversity. These strengths have propelled the country to become one of the world’s leading producers of crops such as rice and wheat. However, farmers in the country face significant challenges – from erratic monsoons, severe droughts and unseasonal rains compounded by El Nino, to pests and diseases that destroy an estimated 30 percent of crops annually. More than 80 percent of India’s estimated 150 million farming households are composed of smallholder farmers who operate on less than two hectares of land. This limits economies of scale, sets obstacles to the wider adoption of advanced technologies and could widen a systemic gap between large commercial agricultural operations and the bulk of its farming population. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202606151544
Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 10:00:00 EEST | Press release
Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discovery teams to accelerate decision-making, streamline workflows, and advance programs more efficiently from hit identification through lead optimization. "Drug discovery increasingly requires seamless integration between chemistry and biology," said Michael Dabrowski, Chief Executive Officer of Pelago Bioscience. "By bringing RG Discovery
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
